Plain-English translation of NCT06696170 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing the CellFX Nano-PFA 360 Catheter, a new device that uses nanosecond pulsed electrical energy to treat atrial fibrillation—a condition where your heart beats irregularly. The treatment works by carefully isolating the pulmonary veins (blood vessels that bring blood into your heart) to stop the abnormal electrical signals causing the irregular heartbeat. This is the first study in humans to see if this new approach is safe and works effectively.
Current treatments for atrial fibrillation—like medications and older ablation techniques—don't work for everyone, and some patients have trouble tolerating the side effects. This trial exists to test whether this newer technology offers a better, safer option for people whose condition hasn't responded to standard drug treatments.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will undergo the new catheter ablation procedure, which involves threading a thin tube through a vein to your heart and using electrical energy to isolate the pulmonary veins. Afterward, you'll have heart imaging performed right away to confirm the veins are properly isolated, and again at 3 months to check that the isolation is holding. You'll be followed closely for up to 12 months with regular visits to monitor your heart rhythm and watch for any side effects.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
Belgium
Czechia
Italy